Tesetaxel With Reduced-dose Capecitabine Improved Progression-free Survival in Metastatic Breast Cancer

Tesetaxel With Reduced-dose Capecitabine Improved Progression-free Survival in Metastatic Breast Cancer
Odonate Therapeutics announced that tesetaxel, together with a reduced dose of capecitabine, improved progression-free survival in metastatic breast cancer patients taking part in a Phase 3 clinical trial. Median progression-free survival (PFS) — the time lived until disease progression or death due to any cause — improved by 2.9 months on the combined therapy regimen as compared to capecitabine alone, rising to 9.8 months from 6.9 months. The risk of disease progression or death fell by 28.4% on the combined regimen. The trial, dubbed CONTESSA (NCT03326674), compared tesetaxel with a reduced dose of capecitabine (branded Xeloda, with generics available) — both administered orally — to the standard approved dose of capecitabine alone. It involved 685 patients 18 and older with human epidermal growth factor receptor 2 (HER2) negative, hormone receptor (HR) positive locally advanced or metastatic breast cancer previously treated with a taxane in the neoadjuvant (pre-surgery) or adjuvant setting. Where indicated, participants also must have received endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor. Tesetaxel is an investigational chemotherapy belonging to a class of compounds
Subscribe or to access all post and page content.